Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides
NCT ID: NCT00728338
Last Updated: 2008-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2003-06-30
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diets rich in omega-3 fatty acids have been shown to be cardio-protective; these diets decreased inflammation, platelet aggregation, cardiac arrhythmias, triglycerides, number of total LDL and small dense LDL particles, and increased omega-3 index, endothelial relaxation and atherosclerotic plaque stability. Most of the earlier studies regarding the effects of long chain n-3 PUFA on blood lipids were conducted with fish oils which contain a mixture of EPA and DHA. Recently a number of studies have been conducted with EPA and DHA individually. Results from studies with individual fatty acids show that EPA and DHA have similar effects on some of the lipid parameters, but they are assimilated to a different concentration in tissues and have different effects on lipoprotein particle size, heart rate and blood pressure. The main purpose of this study is to examine the effects of DHA supplementation on the above three risk factors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
Docosahexenoic acid (DHA)
The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
2
7.5 g/ day olive oil
Olive oil
7.5 g olive oil/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Docosahexenoic acid (DHA)
The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
Olive oil
7.5 g olive oil/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* total cholesterol \< 300 mg/dL
* LDL-cholesterol \< 220 mg/dL
* BMI between 22 and 35 Kg/m2
Exclusion Criteria
* antihypertensives
* non sulfonyl urea medications for diabetes mellitus
* drugs that alter serum triacylglycerols and HDL-C levels (i.e. fibrates)
* niacin supplements
* consumers of illegal substances
* consumers of more than 5 drinks of alcohol per week
* more than one fish meal per week
* dietary supplements of fish oil, flaxseed oil or vitamin C or E
39 Years
66 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Northern California Health Care System
FED
DSM Nutritional Products, Inc.
INDUSTRY
USDA, Western Human Nutrition Research Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
USDA, ARS, WHNRC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darshan S Kelley, PhD
Role: PRINCIPAL_INVESTIGATOR
USDA, ARS, WHNRC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Usda, Ars, Whnrc
Davis, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. 2007 Aug;86(2):324-33. doi: 10.1093/ajcn/86.2.324.
Kelley DS, Siegel D, Vemuri M, Chung GH, Mackey BE. Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men. J Nutr. 2008 Jan;138(1):30-5. doi: 10.1093/jn/138.1.30.
Kelley DS, Adkins Y, Woodhouse LR, Swislocki A, Mackey BE, Siegel D. Docosahexaenoic acid supplementation improved lipocentric but not glucocentric markers of insulin sensitivity in hypertriglyceridemic men. Metab Syndr Relat Disord. 2012 Feb;10(1):32-8. doi: 10.1089/met.2011.0081. Epub 2011 Oct 14.
Dawson K, Zhao L, Adkins Y, Vemuri M, Rodriguez RL, Gregg JP, Kelley DS, Hwang DH. Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men. J Nutr Biochem. 2012 Jun;23(6):616-21. doi: 10.1016/j.jnutbio.2011.03.004. Epub 2011 Jul 19.
Related Links
Access external resources that provide additional context or updates about the study.
USDA, ARS, WHNRC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WHNRC002
Identifier Type: -
Identifier Source: org_study_id